Home » news »

The little molecule that could

 

An illustration of an mRNA vaccine molecule.

Photography Do you remember that shining moment when it appeared that the new vaccines against COVID-19 were going to provide a clear, miraculous path out of the pandemic? “There’s nothing like it in all of history,” Eric Topol, M.D., director and founder of the Scripps Research Translational Institute in San Diego, Calif., tweeted. “This will go down as one of science and medical research’s greatest achievements. Perhaps its most impressive.”

Cover art for Gregory Zuckerman's A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine

The development of the vaccines that have saved the lives, health, and sanity of so many is the story that Wall Street Journal reporter Gregory Zuckerman tells us in his new book, A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine. There were no guarantees. Successes in vaccine development have historically been somewhat random, and as AIDS so painfully shows, there have been terrible failures. Additionally, we all know that a great deal went wrong in our response to COVID-19. But, Zuckerman writes, “this is the story of what went right.”

Related stories

  • A black-and-white drawing of a woman balancing on the open pages of a photograph of a book.

  • Photograph of Albert Bourla, CEO of Pfizer.

  • A black-and-white drawing of a woman struggles to walk forward. A photo of the coronavirus cell serves as the ball of a ball and chain on her ankle.

Although the author chronicles other vaccine technologies, the starring role in his story is played But there were a determined few who believed that mRNA could be useful, both in curing disease and as a vaccine, because it could provide a way to give instructions to the body to fight off various pathogens. Way back in 1990, an iconoclastic scientist—a redundant phrase in Zuckerman’s book—named Jon Wolff demonstrated that you could indeed create a functional protein There were a determined few who believed that mRNA could be useful, both in curing disease and as a vaccine, because it could provide a way to instruct the body to fight off pathogens.

Zuckerman also tells the story of many other dogged and similarly iconoclastic scientists who pursued mRNA, along with other underappreciated vaccine technologies that finally proved their worth. Take Katalin Kariko, a Hungarian immigrant who worked as a researcher at the University of Pennsylvania’s medical school. She and a colleague, Drew Weissman, figured out a way to sneak mRNA, which if injected would trigger the immune system to go to war, past the body’s main line of defense. Much to their surprise, few cared.

At almost 60, Kariko left the university to join a startup named BioNTech, which was founded in Germany Science can be a viciously competitive field, even when lives are at stake. Zuckerman takes readers inside the egos and ambitions that are normally invisible to outsiders. He shows how much they all cared about beating the virus—but also how much they cared about beating one another. According to Zuckerman, scientists aren’t so different from Hollywood stars in their fears of fading from the stage. They “battle insecurities and worry their past successes will be eclipsed and future papers will be rejected.” In this case, the quest was to produce a vaccine, but also to be first. Pfizer, as we now know, ended up in a race to the finish with Moderna to produce an mRNA vaccine, as well as with others working on different technologies.

Today, Moderna is practically a household name, with a market value of more than US$100 billion. But before the pandemic, few had heard of it. Within the investment community, the company had a slight reputation of being overly promotional, in part because of the super-salesmanship used Zuckerman writes about the moments we know well, such as when the over-90% efficacy rates of the Pfizer and Moderna vaccines first became public. “The Dow Jones Industrial Average soared, social media lit up, and millions of people around the world breathed deep signs of relief,” he writes. “For the first time in over eight months, they could imagine a return to normalcy.” But the narrative allows us to understand that moment in a whole new way, because Zuckerman shows us the private moments that preceded it. At the interim review of the Pfizer/BioNTech vaccine on Sunday, November 8, 2020, where executives first saw the efficacy data, champagne and tears flowed. “I love you,” Pfizer CEO Albert Bourla screamed out to his colleagues.

Zuckerman is clear at the outset that his goal in writing the book wasn’t to cover every aspect of the pandemic. That said, there’s an odd gap: he largely ignores Operation Warp Speed, or OWS, the US government initiative that guaranteed billions of dollars to companies including Moderna and Novavax in exchange for potential doses of vaccines, thereThe book ends at that euphoric moment when it looked as though the vaccines were salvation. As we all know now, the virus is wily. Although the vaccines are an extraordinary accomplishment, the giddy optimism has curdled into a sour recognition that this isn’t over. But even that knowledge isn’t enough to dampen the optimism that Zuckerman conveys. Because scientists were forced to make vaccines on a timetable that had never been used before, they know much more than they did. Zuckerman quotes Jeremy Farrar, a British medical researcher and director of the Wellcome Trust: “Whole new areas of medicine have opened up. Out of the horror of COVID will come remarkable advances.”

Yes, we hope that’s true.

 

Related Posts

  • No Related Posts